dupilumab (dupixent) Report issue

Biologics mAb Approved FDA First in Class
AACT ChEMBL DrugBank Drugs@FDA MeSH

Active Ingredient History

NOW
  • Now
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis and prurigo nodularis.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$645.0496

United States

$1079.2200 - $3321.1506
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

dupilumab | dupixent | regn668 | regn-668 | sar231893

Organizations (71)

Research & Development (71)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (51)

Approved Indications (1)


 

Dermatitis, Atopic

Experimental Indications - Clinical Trial Phases 1-4 (51)


 

Allergy and Immunology (Phase 2)

Alopecia Areata (Phase 2)

Angioedema (Phase 2)

Aspergillosis, Allergic Bronchopulmonary (Phase 3)

Asthma (Phase 4)

Asthma, Aspirin-Induced (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Chronic Urticaria (Phase 3)

Colitis, Ulcerative (Phase 2)

Conjunctivitis (Phase 2)

COVID-19 (Phase 2)

Dermatitis (Phase 3)

Dermatitis, Allergic Contact (Phase 4)

Dermatitis, Atopic ()

Dermatology (Phase 3)

Eczema (Phase 4)

Eosinophilia (Phase 4)

Eosinophilic Esophagitis (Phase 4)

Eosinophils (Phase 2/Phase 3)

Food Hypersensitivity (Phase 2)

Gastritis (Phase 2/Phase 3)

Gastroenteritis (Phase 2)

Genetic Diseases, Inborn (Phase 3)

Healthy Volunteers (Phase 1)

Hypersensitivity (Phase 3)

Hypersensitivity, Immediate (Phase 3)

Ichthyosis (Phase 4)

Immune System Diseases (Phase 3)

Inflammation (Phase 2/Phase 3)

Keloid (Phase 4)

Lung Diseases (Phase 4)

Nasal Polyps (Phase 2)

Netherton Syndrome (Phase 2/Phase 3)

Neurodermatitis (Phase 3)

Olfactory Nerve Diseases (Phase 4)

Paranasal Sinus Diseases (Phase 2/Phase 3)

Peanut Hypersensitivity (Phase 2)

Pemphigoid, Bullous (Phase 2/Phase 3)

Prostatic Neoplasms (Phase 2)

Pruritus (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Rhinitis, Allergic (Phase 2)

Scleroderma, Localized (Phase 2)

Sinusitis (Phase 4)

Skin Diseases (Phase 3)

Skin Diseases, Eczematous (Phase 3)

Skin Diseases, Genetic (Phase 3)

Sleep Apnea Syndromes (Early Phase 1)

Sleep Disorders, Intrinsic (Phase 4)

Urticaria (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 160
  • # of Trial Organizations: 71

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue